Medtronic (MDT) Expected to Announce Earnings on Wednesday

Medtronic (NYSE:MDT - Get Free Report) is projected to post its Q4 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Medtronic to post earnings of $1.58 per share and revenue of $8.81 billion for the quarter. Medtronic has set its FY 2025 guidance at 5.440-5.500 EPS.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.03. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The firm had revenue of $8.29 billion for the quarter, compared to analysts' expectations of $8.33 billion. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Price Performance

Shares of Medtronic stock opened at $85.26 on Wednesday. The firm has a market cap of $109.35 billion, a PE ratio of 25.91, a PEG ratio of 2.22 and a beta of 0.81. Medtronic has a 12 month low of $75.96 and a 12 month high of $96.25. The stock has a 50 day moving average of $86.43 and a 200 day moving average of $86.72. The company has a current ratio of 1.90, a quick ratio of 1.39 and a debt-to-equity ratio of 0.48.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were paid a $0.70 dividend. The ex-dividend date was Friday, March 28th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.28%. Medtronic's payout ratio is currently 85.11%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Medtronic stock. Brighton Jones LLC lifted its position in Medtronic plc (NYSE:MDT - Free Report) by 1,368.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,989 shares of the medical technology company's stock after purchasing an additional 37,265 shares during the quarter. Brighton Jones LLC's holdings in Medtronic were worth $3,194,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MDT shares. Needham & Company LLC restated a "hold" rating on shares of Medtronic in a report on Wednesday, February 19th. UBS Group boosted their target price on Medtronic from $85.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, February 19th. Royal Bank of Canada reiterated an "outperform" rating and issued a $105.00 price target on shares of Medtronic in a report on Wednesday, February 19th. Citigroup raised Medtronic from a "neutral" rating to a "buy" rating and raised their price target for the stock from $92.00 to $107.00 in a research note on Tuesday, March 4th. Finally, Robert W. Baird upped their price objective on Medtronic from $90.00 to $91.00 and gave the company a "neutral" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Medtronic presently has an average rating of "Hold" and an average price target of $96.14.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.